United States · Bill · HR
H.R. 4553 (116th)
Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act
Introduced
27 September 2019
Last action
—
Status
Referred to the Subcommittee on Health.
Sponsors
—
Subjects
Discovery layer
Source updated
3 January 2025
Summary
Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act This bill expands the priority-review voucher program for tropical diseases to include Middle East respiratory syndrome, Nipah virus, and Rift Valley fever. A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 27 September 2019
Introduced in House (PDF)
Introduced in House · EN · 27 September 2019
Introduced in House
summary · EN · 27 September 2019
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/house-bill/4553
- Open data entity: https://api.congress.gov/v3/bill/116/hr/4553